SILVERBACK THERAPEUTICS STOCK UPDATE

SILVERBACK THERAPEUTICS STOCK UPDATE

Silverback continues to advance discovery programs, with an update anticipated in the fourth quarter of 2022.SBT8230 is designed to elicit a liver-localized anti-viral immune response and has the potential to improve the therapeutic window observed with untargeted, orally administered TLR8 agonists in cHBV, which have shown promise preclinically, but have been limited by toxicities in the clinic associated with immune activation in the gastrointestinal tract. ASGR1 is highly expressed in liver and is restricted in its expression to this organ.

SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to a TLR8 linker-payload. Silverback expects to open enrollment for the single ascending dose healthy volunteer cohort of the Phase 1 study in the first quarter of 2023 and anticipates reporting data from this portion of the study in the second half of 2023. Initiated Phase 1-enabling toxicology study for SBT8230 in the first quarter of 2022 and on track to complete Phase 1 regulatory submission in the fourth quarter of 2022.

SBT8230 (ASGR1-TLR8 ImmunoTAC conjugate for chronic HBV) We plan to report data from this cohort in the second half of 2023.вЂќ Our team is on track to complete a regulatory submission in the fourth quarter of 2022, enabling the planned initiation of the single ascending dose healthy volunteer cohort of the Phase 1 study in the first quarter of 2023. вЂњWe believe that activating the immune response is an important component of a functional cure and may be combined with treatments that target the HBV life cycle to improve durability.

вЂњIn the first quarter of 2022, we have made significant progress in advancing the preclinical development of SBT8230, a first-in-class antibody-drug conjugate that we believe has the potential to drive functional cure in patients with chronic hepatitis B (cHBV) by eliciting a liver-localized anti-viral response,вЂќ said Laura Shawver, Ph.D., chief executive officer of Silverback. (Nasdaq: SBTX) (вЂњSilverbackвЂќ), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended Maand provided a business update.

Silverback therapeutics stock